Lancet Study: South Africa's HPV Vaccination Programme Alters Population-Level Epidemiology

South Africa's HPV Vaccination Milestone: A Game-Changer in Public Health

South Africa's ambitious school-based human papillomavirus (HPV) vaccination programme, launched in 2014, has delivered remarkable results, fundamentally shifting the landscape of HPV-related diseases. Targeting grade 4 girls aged nine and older with two doses of the bivalent vaccine—designed to protect against the high-risk HPV types 16 and 18 responsible for about 70% of cervical cancers—the initiative achieved an impressive first-year coverage of 87% for at least one dose, maintaining levels above 80% thereafter. 71 70 This public health triumph, particularly in a high-HIV-prevalence setting, underscores the power of high-coverage vaccination strategies in low- and middle-income countries.

The programme's success is not just anecdotal; recent evidence from leading South African researchers paints a vivid picture of population-level transformation. Universities like the University of the Witwatersrand (Wits) have been at the forefront, conducting pivotal studies that validate these outcomes and guide future policy.

The Landmark Lancet Study: Quantifying the Impact

A groundbreaking repeat cross-sectional study published in The Lancet Global Health in April 2026 provides the first direct population-level evidence of the programme's effectiveness. Led by researchers including Dorothy A. Machalek from international collaborators and key South African institutions, the study compared HPV prevalence in two birth cohorts of adolescent girls aged 17-18 years: a pre-vaccine group surveyed in 2019 (819 participants) and a post-vaccine group in 2023 (1,538 participants). 71

Conducted across 15 primary health-care clinics in four provinces—Free State, Gauteng, Mpumalanga, and North West—the research spanned diverse settings representative of public health access for 90% of South Africans. Vaccination status was verified through district registers and self-reports, ensuring robust data integrity.

Striking Reductions in Vaccine-Type HPV Prevalence

The headline result: an 83% decline in HPV-16 and HPV-18 prevalence, dropping from 21.6% (177 of 819) in the pre-vaccine era to just 3.2% (49 of 1,538) post-vaccination (adjusted prevalence ratio [aPR] 0.17, 95% CI 0.12–0.24; p<0.0001). This mirrors reductions seen in three-dose programmes in high-income countries, affirming the two-dose schedule's efficacy. 71

Even more compelling, the impact held steady among girls living with HIV—a group at heightened risk for persistent HPV infections and cervical cancer. Prevalence fell from 29.4% (73 of 248) to 4.4% (13 of 295), with an aPR of 0.18 (95% CI 0.10–0.32; p<0.0001). Cross-protection against related types HPV-31 and HPV-45 showed a 59% reduction (aPR 0.41, 95% CI 0.31–0.54), broadening the protective shield.

These findings highlight how timely vaccination before sexual debut delivers equivalent protection regardless of HIV status, bolstered by widespread antiretroviral therapy access.

Herd Immunity: Protecting the Unvaccinated

Beyond direct effects, the study revealed strong herd immunity. Among unvaccinated girls in the post-vaccine cohort, HPV-16/18 prevalence was 74% lower (aPR 0.26, 95% CI 0.15–0.45) than in the pre-vaccine group, demonstrating community-wide benefits from high coverage. This indirect protection is crucial in resource-limited settings, amplifying the programme's reach.

While some non-vaccine types like HPV-51 showed modest increases, no consistent type replacement was observed, supporting the vaccine's causality in prevalence shifts. 71 70

South African Universities Driving the Research

South African higher education institutions are central to this success story. The Wits Reproductive Health and HIV Institute (Wits RHI), part of the University of the Witwatersrand, played a starring role in study coordination and execution. Sinead Delany-Moretlwe and Helen Rees from Wits RHI contributed expertise in HPV epidemiology and vaccine trials. 71

Walter Sisulu University in Mthatha and the University of Pretoria's Department of Paediatrics and Child Health provided critical local insights, ensuring the research reflected real-world diversity. Stellenbosch University's South African Centre for Epidemiological Modelling and Analysis authored a companion Lancet comment, outlining next steps like surveillance and equity monitoring. 70

Earlier Wits-led initiatives, like the first HPV vaccine impact project in Africa (2019), laid the groundwork, evaluating one- and two-dose schedules in community settings. These university efforts position South Africa as a global leader in HPV research amid high HIV burdens.

Navigating Challenges in a High-HIV Context

South Africa's HIV epidemic—where women living with HIV face sixfold higher cervical cancer risk—posed unique hurdles. Yet, the vaccine's performance equaled that in HIV-negative peers, thanks to early vaccination and ART scale-up. No waning immunity signals emerged short-term, though long-term monitoring is urged, especially for HIV-positive individuals.

Private-sector coverage (about 5% of girls) remains opaque without a national register, highlighting data infrastructure gaps. Parasitic infections like schistosomiasis may subtly influence immunity, warranting further probes.

• High initial coverage via schools minimized dropout risks.
• Integration with HIV services enhanced equity.
• Cross-protection extends benefits beyond targeted types.

Towards Cervical Cancer Elimination: WHO Targets and Projections

Cervical cancer claims over 5,900 lives annually in South Africa, with 10,500 new cases. High-coverage HPV vaccination, paired with screening and treatment (90-70-90 WHO targets by 2030), could avert this burden. Models suggest vaccinating boys alongside girls or boosting girls' coverage to 90% yields comparable gains.Read the full Lancet study.

Transitioning to single-dose schedules (WHO-endorsed 2022) simplifies delivery, though three doses may suit HIV-positive girls. Nonavalent vaccines, targeting nine types (85% coverage), promise even greater impact.

Stakeholder Perspectives from SA Academia

"We observed impacts similar to those seen with three-dose programmes in high-income settings, including equivalent impacts among adolescent girls living with HIV," note the authors, emphasizing real-world validation. 71 Stellenbosch researchers advocate integrated monitoring linking vaccination, HIV care, and cancer registries for equity tracking.

Wits experts stress sustained investment: high coverage pre-debut is key, with outreach for marginalized groups. Pretoria's paediatricians highlight adolescent-friendly services' role in success.

Broader Research Ecosystem at SA Universities

Beyond this study, SA universities fuel HPV innovation. UCT researchers link vaccination to screening for sub-Saharan elimination. 53 Stellenbosch models cost-effectiveness of strategies like boy vaccination. Wits RHI's longitudinal work on single-dose efficacy in HIV contexts informs global policy.

Future Outlook: Surveillance, Expansion, and Equity

Next steps include electronic life-course tracking, routine HPV DNA surveillance via antenatal clinics, and private-sector data. Universities must pioneer type-specific monitoring for replacement risks and waning protection. Expanding to boys and catch-up campaigns, alongside self-sampling screens, accelerates elimination.Explore next steps commentary.

Challenges persist: boosting screening linkage (currently low) and addressing HIV synergies. Yet, with university-led innovation, South Africa exemplifies scalable prevention.

Actionable Insights for Researchers and Policymakers

For academics: Leverage Wits-like models for surveillance cohorts; integrate AI for HPV genotyping. Policymakers: Prioritise registers, single-dose rollout, boy inclusion. Students: Pursue public health at SA unis—research jobs abound in epidemiology.

• Invest in university-HIV programme synergies.
• Fund long-term cohort studies.
• Promote gender-neutral vaccination modelling.
• Enhance data platforms for real-time tracking.

This HPV success story from South African universities offers a blueprint for Africa, blending rigorous research with bold public health action.

Photo by Brett Jordan on Unsplash